<DOC>
	<DOCNO>NCT00395655</DOCNO>
	<brief_summary>Aberrant DNA methylation histone deacetylation participate cancer development progression , epigenetic alteration common breast cancer , phase II study , demethylating hydralazine plus HDAC inhibitor magnesium valproate add neoadjuvant doxorubicin cyclophosphamide locally advance breast cancer ass safety biological efficacy .</brief_summary>
	<brief_title>Hydralazine Valproate Added Chemotherapy Breast Cancer</brief_title>
	<detailed_description>Eligible patient sign informed consent undergo study evaluation type acetylator phenotype treat hydralazine 182 mg rapid- , 83 mg slow-acetylators , magnesium valproate 30 mg/kg , start day –7 chemotherapy end . Chemotherapy consist regimen four cycle doxorubicin 60 mg/m2 cyclophosphamide 600 mg/m2 every 21 day , follow surgery assess pathological response . Adjuvant radiation additional treatment do off-protocol basis accord standard institutional policy . Blood sample core-needle biopsy take primary breast tumor diagnosis day 8 treatment hydralazine valproate . Global cytosine content ( global DNA methylation ) histone deacetylase activity assess peripheral blood DNA . The transcriptional profile primary breast tumor treatment also analyze well plasma level hydralazine valproic acid .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Aged 18 old ; histologically proven invasive T23 , N02 , M0 ( stage IIB–IIIA ) breast carcinoma ; Eastern Cooperative Oncology Group performance status ≤2 . Hematological function : Absolute leukocyte count ≥4,000/mm3 , platelets ≥100,000/mm3 , hemoglobin ≥9.0 g/dL . Hepatic function : total bilirubin , aspartate amino transferase alanine amino transferase &lt; 1.5 upper normal limit . Renal function : creatinine ≤1.2 mg/dL calculate creatinine clearance ≥60 mL/min . Written informed consent . A history allergy sulpha , hydralazine , magnesium valproate . Past present condition rheumatic disease , central nervous system disease , heart failure aortic stenosis postural hypotension diagnose physician . Previous use experimental drug . Pregnancy breastfeed . Uncontrolled systemic disease infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>hydralazine</keyword>
	<keyword>magnesium valproate</keyword>
	<keyword>epigenetic therapy</keyword>
	<keyword>gene expression</keyword>
</DOC>